Previous 10 | Next 10 |
Gilead Sciences ( GILD ) has had a rough past five years, judging by its stock price, which peaked back in 2015. However, throughout this period, cash generation has been strong and was used to make a major acquisition, Kite in 2017 and, recently, to make an investment and licensing deal with ...
Galapagos NV ( GLPG ), a Belgium-based biotechnology pharmaceutical development company, recently agreed to a major deal with Gilead Sciences ( GILD ). Galapagos' stock got an immediate, massive price boost, while Gilead was little-affected. This interests me because a fair portion of my portf...
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on July 14, 2019. This press release features multimedia. View the full release here: https://www.businesswi...
Background - why it's just another stock now At its peak in 2014-5, Gilead Sciences ( GILD ) had almost everything going for it. Its HCV drugs had the sales momentum and headlines. And a growing number of analysts were signing on to the argument I put forth in The Importance Of TAF To Gilea...
Gilead Sciences ( GILD -0.4% ) and collaboration partner Galapagos NV ( GLPG ) announce that the European Medicines Agency (EMA) has accepted for review their marketing application for JAK1 inhibitor filgotinib for rheumatoid arthritis. More news on: Gilead Sciences, Inc., Galapag...
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been valida...
Source: Barron's Gilead ( GILD ) has been delivering uneven revenue growth over the last few quarters. Q2 2019 results showed promise, yet they followed an 8% sequential revenue decline in Q1. Gilead is chugging along, but I consider the stock a sell until it can deliver consistent top lin...
Source: Barron's Gilead ( GILD ) reports Q2 earnings July 30th. Analysts expect revenue of $5.51 billion and EPS of $1.72. The revenue estimate implies 4% growth sequentially. Investors should focus on the following key items: HCV Could Show Signs Of Life Gilead has experienced a ste...
KalVista Pharmaceuticals (NASDAQ: KALV ) initiated with Outperform rating and $31 (83% upside) price target at SVB Leerink. More news on: KalVista Pharmaceuticals, Inc., Gilead Sciences, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...
Galapagos NV (GLPG) Q2 2019 Earnings Conference Call July 26, 2019, 08:00 ET Company Participants Elizabeth Goodwin - VP, IR & Corporate Communications Onno van de Stolpe - Co-Founder, MD, CEO & Executive Director Bart Filius - CFO & COO Walid Abi-Saab - Chief Medic...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...